

Contact:

Karen A. Donato, Ph.D.
Executive Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

***MaxCyte® STX™ Scalable Transfection System for Cell Based Assays
in Drug Discovery: Screening Data to be Presented at the 15th Annual
SBS Meeting in Lille, France***

Gaithersburg, MD, April 27, 2009 –MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, will feature the MaxCyte® STX™ Scalable Transfection System at booth 285 at the Society for Biomolecular Sciences (SBS) 15th Annual Conference & Exhibition in Lille, France, April 26-30. The MaxCyte STX is a valuable tool for drug discovery groups to reduce the timeline for the development of biologically relevant cell based assays and to accelerate the screening of compound libraries for drug candidate selection.

In the Introduction to Technology Session, Dr. James Brady, Director of Technical Applications, will be making a technical presentation on Wednesday, April 29 at 10:10 AM, titled “Scalable Electroporation System Transfects Large Volumes of Cells for Cell-Based Assays & Other Drug Screening Applications.” Dr. Brady states, “Stable cells lines have traditionally been used for the development of cell based assays for compound screening. Unfortunately, stable cells lines can take many months to develop, slowing down drug discovery programs. Cells transiently transfected using the MaxCyte STX have been shown to perform equivalently to stably transfected cells in cell based assays. The performance of the cells, combined with the flexibility of cell type, loading agent, and scale, makes the MaxCyte STX a valuable tool for the development and conduct of biologically relevant cell based assays.”

In addition, Doug Doerfler, President and CEO of MaxCyte, will provide a corporate overview of MaxCyte and its propriety cell modification technology in Innovation Plaza at 12:45PM, Tuesday, April 28. “The MaxCyte STX is being viewed by the pharmaceutical industry as an innovative and enabling technology for cell modification for both research and large scale cell-based applications in drug discovery,” says Mr.Doerfler. “The MaxCyte STX is a powerful technology for modifying cells in ways that will improve the design, development, and conduct of cell-based screening assays, increasing the likelihood of finding successful drug candidates.”

MaxCyte will also be demonstrating the MaxCyte STX at booth 285 during the SBS Meeting.

About MaxCyte: MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte® STX™ Scalable Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays and other cell-based applications.

For more information, <http://www.maxcyte.com/cell-based-screening.shtml>.

###